The role of fecal calprotectin in investigating inflammatory bowel diseases

Clinics

Volumn 64, Issue 5, 2009, Pages 421-425

  Erbayrak, Mustafa ^a   Turkay, Cansel ^a   Eraslan, Elife ^a   Cetinkaya, Hulya ^b   Kasapoglu, Benan ^a   Bektas, Mehmet ^b  

^a FATIH UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Fecal calprotectin; Inflammatory bowel diseases; Irritable bowel syndrome

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN;

ADULT; AGED; ARTICLE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67749145174     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009000500009     Document Type: Article

References (15)

1. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol. 1980; 24: 393-8.
2. Satoru Y, Yuichi N.Masaaki Mikami. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003; 266: 753-60.
3. Kruis W, Thieme C, Weinzierl M, Schüssler P, Holl J, Paulus W, et al. A diagnostic score for irritable bowel syndrome: Its value in the exclusion of organic disease. Gastroenterology. 1984; 87: 1-7.
4. Rachmilewitz D: Coated mesalazine (5-ASA) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized trial. BMJ. 1989; 298: 82-86.
5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on therapeutic trial. Br Med J. 1995; 2: 1041-8.
6. Rosent AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Digestive and liver disease. 2003; 35: 607-9.
7. Costa F, Mumola MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-8.
8. Sands BE. Crohn's disease. Sleisenger & Fordtran's gastrointestinal and liver disease 7 th edition, WB Saunders Company. 2002; 103: 2005-38.
9. Jewell DP, Ulcerative colitis. Sleisenger & Fordtran's gastrointestinal and liver disease 7 th edition, WB Saunders Company. 2002; 103: 2039-67.
10. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001; 96: 2113-6.
11. Odes HS, Fich A, Reif S, Halak A, Lavy A, Keter D, et al. Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Dig Dis Sci. 2001; 46: 1717-21.
12. Jewell DP, Ulcerative colitis. Sleisenger & Fordtran's gastrointestinal and liver disease 7 th edition, WB Saunders Company. 2002; 103: 2039-67.
13. Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJ Med. 2005; 98: 435-41.
14. Saverymutti SH. Clinical remission in Crohn's disease- Assesment using faecal Indium- 111 granulocyte excretion. Digestion. 1986; 33: 74-9.
15. Tibble JA, Fagerhol MK, Sigthorsson G, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002; 123: 450-60.